Immunochemical analysis for Ki-67 for a Stat3f/f(B) and Stat3-IKO colon (C)

Immunochemical analysis for Ki-67 for a Stat3f/f(B) and Stat3-IKO colon (C).ArrowsinBindicate Ki-67+cells and inCindicate Ki-67+cells at the tip of the gland. mice required the presence of microflora. Indeed, inflammation was associated with disruption of colonic homeostasis, fulminant epithelial/tumor cell proliferation, and activation of the mammalian target of rapamycin (mTOR)-Stat3 pathway in epithelial and tumor cells. The activation of this pathway was essential for both the excess proliferation of epithelial/tumor cells and the disruption of colonic homeostasis in the mutant mice. Notably, a similar abnormal up-regulation of mTOR-Stat3 signaling was consistently observed in the colonic epithelial cells of human IBD patients with active disease. These studies demonstrate a novel mouse model of IBD-colorectal cancer progression in which disrupted immune regulation, mTOR-Stat3 signaling, and epithelial hyperproliferation are integrated and simultaneously linked to the development of malignancy. Chronic inflammation in the intestine ranks among the top three high-risk conditions for colorectal cancer.1In contrast to the other high-risk conditions, the hereditary syndromes of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, in which the genetic predispositions have been identified, the mechanistic link between inflammation and tumorigenesis is still largely unknown.1 IBD is thought to be an unique modulation of the intestinal mucosal immune response determined by a complex interplay of genetic, microbial, and environmental factors.2Animal models that mimic human IBD and its associated colorectal cancers have contributed to recent progress in the understanding of mucosal immunity and its dysregulation in tumorigenesis.3A number of widely used models involve chemically induced inflammation-associated colorectal cancers, initiated by injecting mice with carcinogens such as azoxymethane and/or introducing chemical irritants such as dextran sulfate sodium.3Such treatments lead to acute inflammation in the intestine promoted by mucosal damage induced by the chemical, rather than chronic inflammation as observed in patients with IBD, and therefore may not recapitulate stochastic events involved in inflammation-associated cancers in the human.4 An alternative approach is to model IBD by genetic modifications that favor the development of chronic intestinal inflammation. Signaling through interleukin (IL) 10, an anti-inflammatory cytokine, has been targeted, because evidence indicates that this cytokine is important in maintaining the hyporesponsive state of the intestinal mucosa to normal bacterial microflora.5Sequence variants or polymorphisms in theIL-10gene have been reported to contribute to IBD susceptibility,6,7,8indicating that interference with IL-10 regulation may make an important contribution to the etiology of IBD. Indeed, inflammation and tumors develop in the colon ofIL-10/mice in a manner dependent on the presence of intestinal microflora.9However, becauseIL-10deletion is present in all cells in these mice, it is difficult in this model to distinguish effects due to dysregulation of stromal and immune cells from effects arising from IL-10 mutation in the epithelium. To address this issue, attempts have been made to inactivate IL-10 signaling more specifically in cells of the immune system. Signal transducer and activator of transcription 3 (Stat3) plays a major role in Janus tyrosine kinase/Stat signaling induced by IL-10.10Mice with inactivation of Stat3 targeted by interferon-responsive Mx1-Cre to multiple types of cells including macrophages and gut epithelial cells11or targeted to myeloid cells with LysM-Cre, developed colitis in the intestine.12However, unlike inIL-10/mice, targeting Tiagabine of Stat3 inactivation in these mice was not reported to cause tumor formation,11,12suggesting that additional factor(s) are required for prompting tumor development in the colon in the setting of an inflammatory response. In this regard, although IL-10 plays a major role in myeloid cells, the cytokine also inhibits activation and function of T cells, granulocytes, B cells, and natural killer cells,13although mice with T lymphocyte-specific depletion of Stat3 did not develop either colitis or colonic tumors.14 We therefore tested the effect of the conditional inactivation ofStat3floxgenes in immune cells using Cre driven by the colony-stimulating factor-1 receptor promoter.15,16This inactivated Stat3 in both myeloid and lymphoid cells, including macrophages, lymphocytes, and granulocytes, which produced not only a dramatic inflammatory response of the intestine but also eventual malignant tumor formation at a frequency similar to that observed in human IBD patients. These phenotypes were completely dependent on the intestinal microflora. This novel mouse model of human IBD recapitulates the increased probability of tumor development in the colon, an important clinical phenotype in human IBD.1Furthermore, using this model we present the first evidence that the Tiagabine inflammation-associated hyperproliferation of colonic epithelial cells is dependent on the activation of signaling through an mTOR-Stat3 pathway. == Materials and Methods == == Mice == All procedures were conducted in accordance with National Institutes of Health regulations concerning use Mouse monoclonal to INHA and care of experimental animals and approved by the Albert Einstein College of Medicine animal use committee. All of the mice were housed Tiagabine in the pathogen-free barrier facility at Albert Einstein College of Medicine. == Stat3-IKO Mice == To establish the transgenic construct forTg(Csf1r-iCre)jwp, the improved Cre (iCre) sequence17was inserted into ApaI and NotI.